Sign In
Buy OKYO
$1.66
-0.0400 (-2.35%)
At Close: Jun 03, 2026
OKYO Pharma to host event featuring Phase 2 trial results for OK-101 in dry eye disease
09:23am, Thursday, 21'st Mar 2024
OKYO Pharma Ltd (NASDAQ:OKYO) has announced plans to host a Key Opinion Leader (KOL) event on April 9 following the anticipated release of comprehensive efficacy data from its Phase 2 trial of OK-101
OKYO Pharma to Host Key Opinion Leader Event to Discuss New and Comprehensive Data from Phase 2 Dry Eye Disease Trial
07:00am, Thursday, 21'st Mar 2024
- Phase 2 OK-101 efficacy data to be released March 22nd, 2024- -KOL Event to be held on April 9th, 2024 at 12 PM ET- LONDON and NEW YORK, March 21, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDA
OKYO Pharma to release Phase 2 dry eye disease trial results on Friday
08:55am, Wednesday, 20'th Mar 2024
OKYO Pharma Ltd (NASDAQ:OKYO) announced that it will be releasing new and comprehensive data from its Phase 2 trial of its investigational therapeutic OK-101 in dry eye disease on Friday, March 22, wi
OKYO Pharma to Release New and Comprehensive Data from Phase 2 Dry Eye Disease Trial and Host Key Opinion Leader Event
07:00am, Wednesday, 20'th Mar 2024
LONDON and NEW YORK, March 20, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of infla
OKYO Pharma shares surge on FDA clearance of Phase 2 neuropathic corneal pain trial
08:47am, Friday, 09'th Feb 2024
OKYO Pharma Ltd (NASDAQ:OKYO) shares moved higher ahead of Friday's opening bell after the biopharmaceutical firm announced that the US Food and Drug Administration (FDA) has cleared its first Investi
OKYO Pharma Receives FDA Approval of IND for OK-101 in Neuropathic Corneal Pain
07:00am, Friday, 09'th Feb 2024
LONDON and NEW YORK, Feb. 09, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of inflam
OKYO Pharma appoints leading ophthalmologists to its Scientific Advisory Board
09:23am, Wednesday, 31'st Jan 2024
OKYO Pharma Ltd (NASDAQ:OKYO) announced that it has appointed three prominent ophthalmologists and corneal surgeons to its Scientific Advisory Board to advise management on the development of its ther
OKYO Pharma reports 'statistical significance' achieved in Phase 2 trial of OK-101 in dry eye disease
09:56am, Monday, 08'th Jan 2024
OKYO Pharma Ltd (NASDAQ:OKYO) has announced positive safety and efficacy results in its Phase 2 trial of OK-101 ophthalmic solution for the treatment of inflammatory dry eye disease (DED). The trial,
OKYO Pharma to Present at the Biotech Showcase Conference in San Francisco, January 8-10, 2024
09:30am, Friday, 05'th Jan 2024
LONDON and NEW YORK, Jan. 05, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of inflammatory
OKYO Pharma on track as last patient enrolled in trial to treat dry eye disease completes final protocol visit
08:17am, Monday, 04'th Dec 2023
OKYO Pharma Ltd (NASDAQ:OKYO) told investors that it is on track to release top-line results from its phase 2 clinical trial of OK-101 to treat dry eye disease (DED) this month after the last patient
OKYO Pharma files IND application OK-101 to treat Neuropathic Corneal Pain
08:20am, Monday, 09'th Oct 2023
OKYO Pharma Ltd (NASDAQ:OKYO), the clinical-stage drug developer noted, told investors it has filed an Investigational New Drug (IND) application with the US Food and Drug Administration (FDA) for th
LONDON and NEW YORK, Oct. 09, 2023 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical stage biopharmaceutical company developing innovative therapies for the treatment of inflammatory
OKYO Pharma phase II dry eye trial making encouraging progress
07:58am, Thursday, 05'th Oct 2023
OKYO Pharma Ltd (NASDAQ:OKYO), the clinical-stage drug developer, has reported encouraging safety data for its ongoing phase II clinical trial of OK-101, a drug candidate aimed at treating dry eye dis
